Amgen "buy," target price reduced

13.03.07 - Goldman Sachs

NEW YORK, March 13 (newratings.com) - In a research note published yesterday, analysts at Goldman Sachs reiterate their "buy" rating on Amgen Inc (AMGN). The target price has been reduced from $82 to $72.